SARS-CoV-2 mRNA vaccine (RBMRNA)
/ Argorna Pharma
- LARVOL DELTA
Home
Next
Prev
1 to 5
Of
5
Go to page
1
January 11, 2024
A Phase I/II Study to Evaluate a SARS-CoV-2 mRNA Vaccine in Healthy Adults
(clinicaltrials.gov)
- P1/2 | N=480 | Completed | Sponsor: Argorna Pharmaceuticals Co., LTD | Active, not recruiting ➔ Completed | Trial completion date: Dec 2023 ➔ Jul 2023
Trial completion • Trial completion date • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases
January 11, 2024
Evaluate the Safety and Immunogenicity of a SARS-CoV-2 mRNA Vaccine Booster
(clinicaltrials.gov)
- P1 | N=60 | Completed | Sponsor: Argorna Pharmaceuticals Co., LTD | Active, not recruiting ➔ Completed | Trial completion date: Nov 2023 ➔ May 2023
Trial completion • Trial completion date • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases
January 01, 2024
Evaluate the Safety and Preliminary Immunogenicity of a SARS-CoV-2 mRNA Vaccine in Adults
(clinicaltrials.gov)
- P1 | N=60 | Active, not recruiting | Sponsor: Argorna Pharmaceuticals Co., LTD
Trial completion date • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases
June 15, 2023
A Phase I/II Study to Evaluate a SARS-CoV-2 mRNA Vaccine in Healthy Adults
(clinicaltrials.gov)
- P1/2 | N=480 | Active, not recruiting | Sponsor: Argorna Pharmaceuticals Co., LTD
New P1/2 trial • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases
June 09, 2023
Evaluate the Safety and Preliminary Immunogenicity of a SARS-CoV-2 mRNA Vaccine in Adults
(clinicaltrials.gov)
- P1 | N=60 | Active, not recruiting | Sponsor: Argorna Pharmaceuticals Co., LTD
New P1 trial • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases
1 to 5
Of
5
Go to page
1